Scientists may have discovered an unexpected new use for one of today’s best-known diabetes and weight-loss medicines.
A new clinical trial suggests that oral semaglutide may help people with alcohol use disorder reduce heavy drinking and alcohol cravings, offering hope for patients who have struggled with existing treatments.
The findings were published in The American Journal of Psychiatry by researchers from the University of Colorado Anschutz Medical Campus. They arrive at a time when doctors urgently need better treatments because no new medicine has been approved specifically for alcohol use disorder in almost twenty years.
Alcohol use disorder is much more than drinking too much. It is a chronic medical condition that changes the brain, making it difficult for people to stop drinking despite serious health, family and social consequences. Millions of adults live with the condition, and relapse is common even after treatment.
Semaglutide was first developed for diabetes and later became popular for weight loss. Researchers believe it affects brain pathways involved in reward, appetite and cravings, raising the possibility that it might also reduce the desire to drink alcohol.
The study enrolled 50 adults with moderate-to-severe alcohol use disorder. Participants were randomly assigned to receive either oral semaglutide or a placebo for eight weeks in a carefully controlled clinical trial.
Compared with the placebo group, people taking semaglutide had fewer heavy drinking days, consumed less alcohol when drinking, experienced fewer cravings and reported fewer alcohol-related problems. Researchers also observed fewer cannabis use days, suggesting the medicine may influence addictive behaviours more broadly.
The treatment was generally safe and well tolerated. Most side effects were mild, and participants showed excellent adherence, indicating that taking the tablet each day was practical for most people.
Researchers caution that the results should not be viewed as final proof. Because the study was relatively small and lasted only two months, larger trials involving more diverse groups of patients are needed to confirm the findings and determine the best treatment approach.
If future studies produce similar results, oral semaglutide could provide doctors with an important new option. Some patients may benefit even if they are not aiming for complete abstinence, since reducing heavy drinking alone can improve health, relationships and quality of life.
This research is exciting because it explores an entirely new use for an established medicine. The study’s strongest feature is its rigorous randomised, double-blind, placebo-controlled design, which provides reliable evidence.
However, the small sample size and short duration mean the findings should be interpreted cautiously until confirmed by larger studies. If future trials are successful, oral semaglutide may reshape the treatment of alcohol use disorder and offer new hope to many patients and families.
If you care about alcoholism, please read studies that your age may decide whether alcohol is good or bad for you, and people over 40 need to prevent dangerous alcohol/drug interactions.
For more information about alcohol, please see recent studies about moderate alcohol drinking linked to high blood pressure, and results showing this drug combo shows promise for treating alcoholism.
Source: University of Colorado Anschutz Medical Campus.
